Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG ® Achieving JPY 5 billion Net Sales in Japan
Poxel eligible for royalties equaling 10% of all TWYMEEG ® net sales for 20241 and a one-time sales-based…